A phase 3 trial evaluated the efficacy and safety of remdesivir for 5 or 10 days in hospitalized patients with severe COVID-19. The study included 397 patients, with 200 receiving 5 days of treatment and 197 receiving 10 days. Both groups received 200 mg on day 1 and 100 mg daily thereafter. The primary endpoint was clinical status on day 14, assessed on a 7-point ordinal scale. At day 14, 64% of patients in the 5-day group and 54% in the 10-day group showed clinical improvement of 2 points or more. After adjusting for baseline clinical status, the distributions of clinical status were similar between the two groups. The most common adverse events were nausea, worsening respiratory failure, elevated alanine aminotransferase levels, and constipation. The trial found no significant difference in efficacy between the 5-day and 10-day regimens. However, the absence of a placebo control means the true benefit of remdesivir cannot be determined. The study suggests that remdesivir may not be more effective for patients not requiring mechanical ventilation, but further research is needed for those requiring it. Safety concerns included elevated liver enzymes and renal toxicity, particularly in the 10-day group. The trial was open-label, and patients were discharged as soon as medically appropriate, which may have influenced outcomes. The results indicate that remdesivir may be effective for 5 days, but longer treatment does not provide additional benefit for non-ventilated patients. The study highlights the need for further research to determine the optimal duration of remdesivir treatment for different patient groups.A phase 3 trial evaluated the efficacy and safety of remdesivir for 5 or 10 days in hospitalized patients with severe COVID-19. The study included 397 patients, with 200 receiving 5 days of treatment and 197 receiving 10 days. Both groups received 200 mg on day 1 and 100 mg daily thereafter. The primary endpoint was clinical status on day 14, assessed on a 7-point ordinal scale. At day 14, 64% of patients in the 5-day group and 54% in the 10-day group showed clinical improvement of 2 points or more. After adjusting for baseline clinical status, the distributions of clinical status were similar between the two groups. The most common adverse events were nausea, worsening respiratory failure, elevated alanine aminotransferase levels, and constipation. The trial found no significant difference in efficacy between the 5-day and 10-day regimens. However, the absence of a placebo control means the true benefit of remdesivir cannot be determined. The study suggests that remdesivir may not be more effective for patients not requiring mechanical ventilation, but further research is needed for those requiring it. Safety concerns included elevated liver enzymes and renal toxicity, particularly in the 10-day group. The trial was open-label, and patients were discharged as soon as medically appropriate, which may have influenced outcomes. The results indicate that remdesivir may be effective for 5 days, but longer treatment does not provide additional benefit for non-ventilated patients. The study highlights the need for further research to determine the optimal duration of remdesivir treatment for different patient groups.